Skip to main content
Erschienen in: Clinical and Experimental Nephrology 2/2013

01.04.2013 | Original Article

The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects

verfasst von: Hirokazu Kakuda, Keizo Kanasaki, Daisuke Koya, Noboru Takekoshi

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Chronic kidney disease (CKD) is a serious health problem worldwide. Therapies that can halt the progression of CKD are limited, and the identification of new strategies for CKD treatment is therefore important. Pitavastatin, one of the newest statins introduced to the market, has been shown to exhibit some beneficial effects on renal and endothelial function.

Method

We enrolled 12 healthy volunteers for our study. With or without pitavastatin administration, creatinine clearance (Ccr), urinary albumin excretion, lipid status, and oxidative stress markers were evaluated in acute and early phases after administration of the drug.

Results

A single pitavastatin administration increased Ccr and reduced oxidative stress parameters, such as 8-OHdG levels and isoprostane production, within 6 h, without altering lipid status in healthy participants. A two-week treatment with pitavastatin lowered total and LDL cholesterol and triglycerides but not HDL cholesterol at 7 and 14 days. This change in lipid profile is associated with enhanced Ccr and the suppression of oxidative stress parameters. Urinary albumin excretion was reduced after either acute or chronic administration of pitavastatin, although this effect was not yet significant.

Conclusion

We found that pitavastatin augmented Ccr and reduced oxidative stress parameters in healthy subjects. These data suggest that pitavastatin affects renal outcomes in both lipid status-dependent and -independent manners. These observations suggest that pitavastatin treatment could be beneficial for CKD patients.
Literatur
1.
Zurück zum Zitat Parker TF 3rd, Blantz R, Hostetter T, Himmelfarb J, Kliger A, Lazarus M, et al. The chronic kidney disease initiative. J Am Soc Nephrol. 2004;15(3):708–16.PubMedCrossRef Parker TF 3rd, Blantz R, Hostetter T, Himmelfarb J, Kliger A, Lazarus M, et al. The chronic kidney disease initiative. J Am Soc Nephrol. 2004;15(3):708–16.PubMedCrossRef
2.
Zurück zum Zitat Makino H, Yasuda Y, Matsuo S. Challenges to chronic kidney disease in Japan: Japan Association of Chronic Kidney Disease Initiative (J-CKDI). Nihon Jinzo Gakkai Shi. 2006;48(8):711–3.PubMed Makino H, Yasuda Y, Matsuo S. Challenges to chronic kidney disease in Japan: Japan Association of Chronic Kidney Disease Initiative (J-CKDI). Nihon Jinzo Gakkai Shi. 2006;48(8):711–3.PubMed
3.
Zurück zum Zitat Heart-Protection-Study-Collaborative-Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002360(9326):7–22. Heart-Protection-Study-Collaborative-Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002360(9326):7–22.
4.
Zurück zum Zitat Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16(12):3748–54.PubMedCrossRef Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16(12):3748–54.PubMedCrossRef
5.
Zurück zum Zitat Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131–9.PubMedCrossRef Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131–9.PubMedCrossRef
6.
Zurück zum Zitat Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis Off J Nat Kidney Found. 2009;54(5):810–9.CrossRef Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis Off J Nat Kidney Found. 2009;54(5):810–9.CrossRef
7.
Zurück zum Zitat Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.PubMedCrossRef Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.PubMedCrossRef
8.
Zurück zum Zitat Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–87.PubMedCrossRef Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–87.PubMedCrossRef
9.
10.
Zurück zum Zitat Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection—more than just lipid lowering? Pharmacol Ther. 2009;122(1):30–43.PubMedCrossRef Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection—more than just lipid lowering? Pharmacol Ther. 2009;122(1):30–43.PubMedCrossRef
11.
Zurück zum Zitat Romayne Kurukulasuriya L, Athappan G, Saab G, Whaley Connell A, Sowers JR. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. Ther Adv Cardiovasc Dis. 2007;1(1):49–59.PubMedCrossRef Romayne Kurukulasuriya L, Athappan G, Saab G, Whaley Connell A, Sowers JR. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. Ther Adv Cardiovasc Dis. 2007;1(1):49–59.PubMedCrossRef
12.
Zurück zum Zitat da Silva PM. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. Am J Cardiovasc Drugs. 2011;11(2):93–107.PubMedCrossRef da Silva PM. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. Am J Cardiovasc Drugs. 2011;11(2):93–107.PubMedCrossRef
13.
Zurück zum Zitat Douglas K, O’Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145(2):117–24.PubMedCrossRef Douglas K, O’Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145(2):117–24.PubMedCrossRef
14.
Zurück zum Zitat Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.PubMedCrossRef Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.PubMedCrossRef
15.
Zurück zum Zitat Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978–86.PubMedCrossRef Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978–86.PubMedCrossRef
16.
17.
Zurück zum Zitat Kojima J, Fujino H, Abe H, Yosimura M, Kanda H, Kimata H. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull. 1999;22(2):142–50.PubMedCrossRef Kojima J, Fujino H, Abe H, Yosimura M, Kanda H, Kimata H. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull. 1999;22(2):142–50.PubMedCrossRef
18.
Zurück zum Zitat Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006;23(3):506–12.PubMedCrossRef Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006;23(3):506–12.PubMedCrossRef
19.
Zurück zum Zitat Arao K, Yasu T, Umemoto T, Jinbo S, Ikeda N, Ueda S, et al. Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circ J. 2009;73(8):1523–30.PubMedCrossRef Arao K, Yasu T, Umemoto T, Jinbo S, Ikeda N, Ueda S, et al. Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circ J. 2009;73(8):1523–30.PubMedCrossRef
20.
Zurück zum Zitat Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol. 2008;125(1):136–8.PubMedCrossRef Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol. 2008;125(1):136–8.PubMedCrossRef
21.
Zurück zum Zitat Yoshida O, Kondo T, Kureishi-Bando Y, Sugiura T, Maeda K, Okumura K, et al. Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circ J. 2010;74(1):195–202.PubMedCrossRef Yoshida O, Kondo T, Kureishi-Bando Y, Sugiura T, Maeda K, Okumura K, et al. Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circ J. 2010;74(1):195–202.PubMedCrossRef
22.
Zurück zum Zitat Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy—Part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovasc Surg. 2010;44(4):241–51.CrossRef Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy—Part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovasc Surg. 2010;44(4):241–51.CrossRef
23.
Zurück zum Zitat Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol. 1996;270(5 Pt 2):F845–51.PubMed Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol. 1996;270(5 Pt 2):F845–51.PubMed
25.
Zurück zum Zitat Righetti M, Sessa A. Cigarette smoking and kidney involvement. J Nephrol. 2001;14(1):3–6.PubMed Righetti M, Sessa A. Cigarette smoking and kidney involvement. J Nephrol. 2001;14(1):3–6.PubMed
26.
Zurück zum Zitat Dobrian AD. ADMA and NOS regulation in chronic renal disease: beyond the old rivalry for l-arginine. Kidney Int. 2012;81(8):722–4.PubMedCrossRef Dobrian AD. ADMA and NOS regulation in chronic renal disease: beyond the old rivalry for l-arginine. Kidney Int. 2012;81(8):722–4.PubMedCrossRef
27.
Zurück zum Zitat Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, Aoki Y, et al. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int. 2012;81(8):762–8.PubMedCrossRef Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, Aoki Y, et al. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int. 2012;81(8):762–8.PubMedCrossRef
28.
Zurück zum Zitat Prowle JR, Ishikawa K, May CN, Bellomo R. Renal plasma flow and glomerular filtration rate during acute kidney injury in man. Ren Fail. 2010;32(3):349–55.PubMedCrossRef Prowle JR, Ishikawa K, May CN, Bellomo R. Renal plasma flow and glomerular filtration rate during acute kidney injury in man. Ren Fail. 2010;32(3):349–55.PubMedCrossRef
29.
Zurück zum Zitat Conrad KP. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J Soc Gynecol Invest. 2004;11(7):438–48.CrossRef Conrad KP. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J Soc Gynecol Invest. 2004;11(7):438–48.CrossRef
30.
Zurück zum Zitat Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, Luno J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008;111:S4–9.PubMedCrossRef Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, Luno J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008;111:S4–9.PubMedCrossRef
31.
Zurück zum Zitat Umeji K, Umemoto S, Itoh S, Tanaka M, Kawahara S, Fukai T, et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol Heart Circ Physiol. 2006;291(5):H2522–32.PubMedCrossRef Umeji K, Umemoto S, Itoh S, Tanaka M, Kawahara S, Fukai T, et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol Heart Circ Physiol. 2006;291(5):H2522–32.PubMedCrossRef
32.
Zurück zum Zitat Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology. 2007;148(1):160–5.PubMedCrossRef Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology. 2007;148(1):160–5.PubMedCrossRef
33.
Zurück zum Zitat Yagi S, Akaike M, Aihara K, Ishikawa K, Iwase T, Ikeda Y, et al. Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension. 2010;55(4):918–23.PubMedCrossRef Yagi S, Akaike M, Aihara K, Ishikawa K, Iwase T, Ikeda Y, et al. Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension. 2010;55(4):918–23.PubMedCrossRef
34.
Zurück zum Zitat Ren Y, Carretero OA, Garvin JL. Mechanism by which superoxide potentiates tubuloglomerular feedback. Hypertension. 2002;39(2 Pt 2):624–8.PubMedCrossRef Ren Y, Carretero OA, Garvin JL. Mechanism by which superoxide potentiates tubuloglomerular feedback. Hypertension. 2002;39(2 Pt 2):624–8.PubMedCrossRef
35.
Zurück zum Zitat Honjo T, Inoue N, Shiraki R, Kobayashi S, Otsui K, Takahashi M, et al. Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res. 2006;43(2):131–8.PubMedCrossRef Honjo T, Inoue N, Shiraki R, Kobayashi S, Otsui K, Takahashi M, et al. Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res. 2006;43(2):131–8.PubMedCrossRef
Metadaten
Titel
The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects
verfasst von
Hirokazu Kakuda
Keizo Kanasaki
Daisuke Koya
Noboru Takekoshi
Publikationsdatum
01.04.2013
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 2/2013
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0689-0

Weitere Artikel der Ausgabe 2/2013

Clinical and Experimental Nephrology 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.